ViiV Healthcare $GSK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS15
PHASE 3 / 2-39
RECRUITING5
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO30%
Delay Index: of 10 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.2 months). See all sponsors →
Open ViiV Healthcare on the live radar map → 📅 $GSK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| BMS-663068 NCT02362503 |
P3 | Active, not recruiting | HIV Infections | 371 | 2016-08-18 (-5 mo) |
| Cabotegravir (CAB) tablet NCT02951052 |
P3 | Active, not recruiting | Infection, Human Immunodeficiency Virus; HIV Infections | 618 | 2018-05-29 (-2 mo) |
| Cabotegravir (CAB) tablet NCT02938520 |
P3 | Active, not recruiting | HIV Infections | 631 | 2018-08-30 (+2 mo) |
| ATLAS-2M NCT03299049 |
P3 | Active, not recruiting | HIV Infections | 1049 | 2019-06-06 |
| VOGUE NCT05979311 |
P3 | Active, not recruiting | HIV; HIV Infections | 463 | 2026-04-15 (+8 mo) |
| EMBRACE NCT05996471 |
P2 | Active, not recruiting | HIV Infections | 185 | 2026-05-27 (+19 mo) |
| Dolutegravir/Rilpivirine FDC NCT05674656 |
P1/2 | Recruiting | HIV Infections | 20 | 2026-06-01 |
| CROWN NCT06694805 |
P3 | Active, not recruiting | HIV Infections | 326 | 2026-08-19 (+3 mo) |
| CAB LA NCT06741397 |
P2 | Active, not recruiting | HIV Infections | 229 | 2026-09-09 |
| VH4524184 NCT07202546 |
P2 | Recruiting | HIV Infections | 186 | 2027-10-28 (+5 mo) |
| PALISADE NCT06134362 |
P3 | Active, not recruiting | HIV Infections | 2998 | 2029-03-14 (+23 mo) |
| CAB ULA NCT07650916 |
P3 | Recruiting | HIV | 564 | 2029-08-13 |
| CABNATE NCT07275606 |
P1/2 | Recruiting | HIV Infections | 44 | 2029-10-10 |
| CINERGY NCT07816250 |
P2 | Not yet recruiting | HIV Infections | 200 | 2032-06-10 |
| PATH NCT07393659 |
P3 | Recruiting | HIV Infections | 197 | 2032-09-14 |